logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11497759 B1

PDFFull Text
Date of Patent:
Nov. 15, 2022

Filed:

Nov. 29, 2018

Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Applicant:

Lunella Biotech, Inc., Ottawa, CA;

Inventors:

Michael P. Lisanti, Fulton, MD (US);

Federica Sotgia, Fulton, MD (US);

Assignee:

LUNELLA BIOTECH, INC., Ontario, CA;

Attorney:

Nixon & Vanderhye, P.C.

Primary Examiner:

Yih-Horng Shiao

Int. Cl.
CPC ...
A61K 31/7048 (2006.01); A61K 31/122 (2006.01); A61K 31/138 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/4025 (2006.01); A61K 31/44 (2006.01); A61K 31/4535 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/506 (2006.01); A61K 31/65 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 31/122 (2013.01); A61K 31/138 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/4025 (2013.01); A61K 31/44 (2013.01); A61K 31/4535 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 31/65 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01);
Abstract

A therapeutic compound having intrinsic anti-mitochondrial properties may be chemically modified to target the compound to mitochondria, and the resulting 'repurposcins' may have enhanced anti-cancer properties, among other advantageous properties. For example, a repurposcin may be used to treat and/or prevent tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance. Described herein are repurposcin compounds and pharmaceutical compositions that have been developed according to the present approach. Also described are methods for identifying and developing repurposcins, methods of using repurposcins to target cancer stem cells, and compositions for treating cancer containing one or more repurposcins as the active ingredient.

Find Patent Forward Citations

Loading…